| Non-Small Cell Lung Carcinoma
Mektovi vs Xalkori
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Mektovi vs Xalkori with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXalkori has a higher rate of injection site reactions vs Mektovi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xalkori but not Mektovi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Mektovi
Xalkori
At A Glance
Oral
Twice daily
MEK inhibitor
Oral
Twice daily
ALK/ROS1 inhibitor
Indications
- melanoma
- Non-Small Cell Lung Carcinoma
- Non-Small Cell Lung Carcinoma
- Ki-1+ Anaplastic Large Cell Lymphoma
- Inflammatory Myofibroblastic Tumor
Dosing
melanoma 45 mg orally twice daily in combination with encorafenib; reduce to 30 mg orally twice daily for patients with moderate or severe hepatic impairment.
Non-Small Cell Lung Carcinoma 45 mg orally twice daily in combination with encorafenib.
Non-Small Cell Lung Carcinoma Adults: 250 mg orally twice daily until disease progression or unacceptable toxicity.
Ki-1+ Anaplastic Large Cell Lymphoma Pediatric patients 1 year of age and older and young adults: 280 mg/m2 orally twice daily (BSA-based dosing) until disease progression or unacceptable toxicity.
Inflammatory Myofibroblastic Tumor Adults: 250 mg orally twice daily; pediatric patients 1 year of age and older: 280 mg/m2 orally twice daily (BSA-based dosing), until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) fatigue, nausea, diarrhea, vomiting, abdominal pain, musculoskeletal pain, visual impairment, constipation, dyspnea, rash, cough
Serious hemorrhage, diarrhea, anemia, dyspnea, pneumonia, arrhythmia, device related infection, edema, myocardial infarction, pleural effusion
Most common (>=25%) Vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, neuropathy.
Serious Hepatotoxicity, interstitial lung disease/pneumonitis, QT interval prolongation, bradycardia, severe visual loss, gastrointestinal toxicity (in pediatric/young adult ALCL or pediatric IMT patients).
Postmarketing Increased blood creatine phosphokinase.
Pharmacology
Binimetinib is a reversible inhibitor of MEK1 and MEK2, upstream regulators of the ERK pathway; combined with encorafenib it targets two different kinases in the RAS/RAF/MEK/ERK pathway for greater anti-proliferative and anti-tumor activity in BRAF mutation-positive tumors.
Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, ROS1, c-Met, and RON; it blocks ALK fusion protein-driven oncogenic signaling, inhibiting tumor cell proliferation and survival.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Mektovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Xalkori
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Mektovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Xalkori
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Mektovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Xalkori
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Mektovi Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MektoviView full Mektovi profile
XalkoriView full Xalkori profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.